How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,546 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease (PubMed)

The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease Viral mutations acquired during the course of chronic hepatitis B virus (HBV) infection are known to be associated with the progression and severity of HBV-related liver disease. This study of HBV-infected Saudi Arabian patients aimed to identify amino acid substitutions within the precore/core (preC/C) region of HBV, and investigate their impact on disease progression toward (...) immuno-active epitopes; E77Q, A80I/T/V, and L116I were located within B-cell epitopes, and F24Y, E64D, and V91S/T were located within T-cell epitopes. Multivariate risk analysis confirmed that the core mutations A80V and L116I were both independent predictors of HBV-associated liver disease progression. In conclusion, our data show that mutations within the preC/C region, particularly within the immuno-active epitopes, may contribute to the severity of liver disease in patients with chronic hepatitis

Full Text available with Trip Pro

2018 Frontiers in cellular and infection microbiology

162. Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population (PubMed)

Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population Innate immunity can induce spontaneous hepatitis B surface antigen (HBsAg) seroclearance (SC) of hepatitis B virus (HBV) infection or transition towards an inactive carrier state. Toll-like receptor (TLR) 3 signalling has been linked to these processes. Alterations in the TLR3 gene might impair immune responses against HBV. In our study, we analysed (...) of developing chronic hepatitis B. In haplotype analysis, the haplotype including both risk variants rs3775291A and rs5743305A had the lowest likelihood of HBsAg SC. Further research in larger cohorts and functional analyses are needed to shed light on the impact of TLR3 signalling.

Full Text available with Trip Pro

2018 Scientific reports

163. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies (PubMed)

Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies The clinical outcome of hepatitis B virus (HBV) infection depends on the success or failure of the immune responses to HBV, and varies widely among individuals, ranging from asymptomatic self-limited infection, inactive carrier state, chronic hepatitis, cirrhosis, hepatocellular carcinoma, to liver failure, depending on the success or failure of immune response to HBV. Genome-wide (...) association studies (GWAS) identified key genetic factors influencing the pathogenesis of HBV-related traits. In this review, we discuss GWAS for persistence of HBV infection, antibody response to hepatitis B vaccine, and HBV-related advanced liver diseases. HBV persistence is associated with multiple genes with diverse roles in immune mechanisms. The strongest associations are found within the classical human leukocyte antigen (HLA) genes, highlighting the central role of antigen presentation

Full Text available with Trip Pro

2018 World Journal of Gastroenterology

164. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease (NAFLD): a population-based cohort study. (PubMed)

Hepatitis B virus infection and risk of non-alcoholic fatty liver disease (NAFLD): a population-based cohort study. Although non-alcoholic fatty liver disease (NAFLD) has been studied extensively, the potential risk factors for NAFLD among chronic hepatitis B (CHB) patients have not been fully known.A population-based cohort of adult CHB patients without a history of alcohol drinking or NAFLD were recruited and followed up from October 2012 to January 2015 in Jiangsu province, China. Using Cox (...) , 8.52; 95%CI, 5.93-12.25) compared to normal weight carriers. The incidence of NAFLD was associated with concurrent type 2 diabetes mellitus (DM) (HR, 1.88; 95%CI, 1.15-3.08). However, no associations between viral factors with NAFLD incidence rate were identified. In a subgroup of participants with concurrent type 2 DM, detectable HBV DNA levels were negatively associated with the development of NAFLD (HR, 0.37; 95%CI, 0.14-0.98). There was super-multiplicative interaction between BMI and gender

2018 Liver International

165. Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program (PubMed)

Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program In this study, the long-term efficacy of hepatitis B virus (HBV) vaccination was assessed using seroprevalence and an age-period-cohort (APC) model of HBV seromarkers among university entrants 30 years after the introduction of the national neonatal HBV vaccination program in Taiwan.In total, data of 17,611 university entrants who underwent university entrance health examinations (...) between 2005 and 2016 were included. The seroprevalence of the HBV surface antigen (HBsAg) and the levels of the antibody against the HBV surface antigen (anti-HBs) in each year group and sex were calculated. The levels of the antibody against the HBV core antigen were examined only for 2012 and 2016. The APC model was used to analyze the HBV carrier rates.The chronic HBV infection (HBsAg positivity) rate decreased from 9.7% in university students born before June 1974 to <1.0% in students born after

Full Text available with Trip Pro

2018 PeerJ

166. Hepatitis B surface antigen-specific cell-mediated immune responses in human chronic hepatitis B surface antigen carriers. (PubMed)

Hepatitis B surface antigen-specific cell-mediated immune responses in human chronic hepatitis B surface antigen carriers. The presence of hepatitis B surface antigen (HBsAg) and antibody (anti-HBs), hepatitis B e antigen (HBeAg) and antibody (anti-HBe), the nature of T-cell function, and specific cell-mediated immunity to HBsAg were determined and evaluated serially in groups of subjects with chronic HBsAg carrier states and in seronegative controls. The techniques of in vitro lymphocyte (...) transformation, spontaneous rosette formation, radioimmunoassay, reverse passive hemagglutination, passive hemagglutination, rheophoresis, and liver function tests were employed for these studies. For the lymphocyte transformation assay, multiple concentrations of phytohemagglutinin and purified HBsAg were used as stimulants. Cell-mediated immunity to HBsAg was detectable in 50% of the chronic HBsAg carriers (responders) at one or more concentrations of HBsAg. The remaining carriers (nonresponders

Full Text available with Trip Pro

1978 Infection and immunity

167. Management of psoriasis patients with hepatitis B or hepatitis C virus infection (PubMed)

Management of psoriasis patients with hepatitis B or hepatitis C virus infection The systemic therapies available for the management of Psoriasis (PsO) patients who cannot be treated with more conservative options, such as topical agents and/or phototherapy, with the exception of acitretin, can worsen or reactivate a chronic infection. Therefore, before administering immunosuppressive therapies with either conventional disease-modifying drugs (cDMARDs) or biological ones (bDMARDs (...) ) it is mandatory to screen patients for some infections, including hepatitis B virus (HBV) and hepatitis C virus (HCV). In particular, the patients eligible to receive an immunosuppressive drug must be screened for the following markers: antibody to hepatitis B core, antibody to hepatitis B surface antigen (anti-HBsAg), HBsAg, and antibody to HCV (anti-HCV). In case HBV or HCV infection is diagnosed, a close collaboration with a consultant hepatologist is needed before and during an immunosuppressive therapy

Full Text available with Trip Pro

2016 World Journal of Gastroenterology

168. Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States (PubMed)

Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States Background : Hepatitis C (HCV) direct acting antiviral agents (DAAs) are safe, effective, and tolerable. Most contraindications to interferon-based treatment are no long applicable. The aims of this study were to understand the predictors of approval to drug accessibility. Methods : We studied all consecutive patients with HCV prescribed DAAs between October 2014 and July 2015. Data on demographic (...) of nonliver comorbidities (OR 2.72, 95% CI 1.35-5.43), and the presence of advanced liver disease (OR 1.82, 95% CI 1.04-3.24) independently predicted drug approval. Conclusion : Despite the availability of DAAs for HCV, barriers from insurance carriers continue to impair widespread use. Patients with advanced liver disease, Medicare, and without comorbidities are most likely to be insurance approved for DAAs.

Full Text available with Trip Pro

2016 Journal of clinical and translational hepatology

169. Chronic hepatitis B infection presenting with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report (PubMed)

pathogenesis. Chronic hepatitis B virus infection has been proposed in correlation with autoimmune diseases, including central nervous system demyelinating disease. Patients with chronic hepatitis B infection may develop the syndrome of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids.A 34-year-old Taiwanese man who had been a hepatitis B virus carrier for a decade presented to our emergency room. He had influenza symptoms and progressive symptoms of left (...) Chronic hepatitis B infection presenting with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids is a brainstem disorder characterized by perivascular pathologic reaction with lymphocyte infiltration and leading to diplopia, facial palsy, dysarthria, and gait ataxia. It was thought to be an autoimmune disorder without distinct

Full Text available with Trip Pro

2015 Journal of medical case reports

170. Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. (PubMed)

Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. Hepatitis B surface antigen (HBsAg) and viral load are both hallmarks of hepatitis B virus (HBV) infection and have potential to stratify liver cancer risk.We carried out a nested case-control study including 211 liver cancer cases and 221 controls who were seropositive for HBsAg within two population-based cohorts in Shanghai. Logistic regression was performed to estimate the odds ratios (...) . Chronic HBsAg carriers may be suggested to simultaneously lower the viral load to < 2000 IU/ml and HBsAg level to < 100 IU/ml to lower their liver cancer risk.© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

2017 Journal of gastroenterology and hepatology

171. The 3-Shot Hepatitis B Vaccine – Do I Need to Restart the Series if I Am Off the Recommended Schedule?

result), but there is no indication of your viral load (HBV DNA) or whether you are experiencing any liver damage. This is indicted by a blood test for the liver enzyme ALT (also called SGPT) or an ultrasound xray of your liver. Please see your doctor about getting these additional tests, then you will be in a better position to judge if your hepatitis B is active — and causing liver damage — or inactive. Good luck. till you develop Hbs Ab = + you are still carrier Hello: If you continue to test (...) work is on the line here. Next time i’ll ask my doctor first before taking any vaccine. my wife has chronic hepatitis B since years back ,and i have completed my three dose vaccine . am i protected fully even if i have direct blood contact? Assuming you generated adequate immunity as a result of your 3 shot vaccination series, you are good. However, if it will put your mind at ease, ask your doctor to test you for HBV. “Assuming you generated adequate immunity as a result of your 3 shot vaccination

2017 hepbblog

172. Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. (PubMed)

Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We (...) of viral hepatitis a global health priority.© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Full Text available with Trip Pro

2017 Liver International

173. Ten Things You Should Know About Hepatitis B and Do in 2017

just discovered you have chronic hepatitis B, which you may have contracted at birth, you need to tell your siblings and your mother and get them screened and immunized if needed. Dating someone, and about to take the next step? You need to disclose ahead of time and give them information and choices. It builds trust and it’s the right thing to do. You would want the same for yourself. For more on disclosure click . Happy 2017! Our hope for a cure continues. As of January 2017, TAF has been (...) a good doctor in japan. if possible please give me some suggestions . Thank you Hello: The Hepatitis B Foundation has a list of liver specialists around the world. Please search for a doctor near you in Japan at: Good luck. Hi Robin Will u please tell me how u reached japan when you r in carrier stage.and what medicine u got from bangladeshi doctor. Thank u When is cure coming? Hello: Not soon enough, but experts around the world are far closer to finding a cure than ever. They predict they will find

2017 hepbblog

174. Facing the Threat of Hepatitis B Following Sexual Coercion or Assault

liver damage, which is indicated by a liver enzyme test for SGPT or ALT in your blood. The best thing you can do for yourself is eat healthy food, avoid alcohol and cigarettes, and get monitored regularly. We are optimistic that in the next few years a cure for hepatitis B will be developed. To keep up to date with the latest in drug developments, please visit our Drug Watch page at: Good luck. Can we get job as a resident doctor in Usa with chronic carrier status ,,,? Hello: Yes you can, the CDC (...) of sexual violence that spreads trauma, fear and diseases such as hepatitis B. However we can, whenever we can, we must work to make a difference. Post navigation Comments on this blog are closed. If you have questions about hepatitis B or this blog post, please email or call 215-489-4900. 13 thoughts on “Facing the Threat of Hepatitis B Following Sexual Coercion or Assault” says: We need more awareness and ways to have people vaccinated against this disease Iam hbv carrier and I vaccinated all three

2017 hepbblog

175. Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. (PubMed)

Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In China, chronic hepatitis B virus (HBV) infection remains the major risk factor for HCC. In this study, we performed a genome-wide association study (GWAS) among Chinese populations to identify novel genetic loci contributing to susceptibility to HBV-related HCC.Experimental (...) Design: GWAS scan is performed in a collection of 205 HBV-related HCC trios (each trio includes an affected proband and his/her both parents), and 355 chronic HBV carriers with HCC (cases) and 360 chronic HBV carriers without HCC (controls), followed by two rounds of replication studies totally consisting of 3,796 cases and 2,544 controls.Results: We identified a novel association signal within the CDK14 gene at 7q21.13 (index rs10272859, OR = 1.28, P = 9.46 × 10-10). Furthermore, we observed

2017 Clinical Cancer Research

176. Immunopathogenesis of Hepatitis B Virus. (PubMed)

Immunopathogenesis of Hepatitis B Virus. Chronic hepatitis B virus (HBV) infection is a global public health issue. There are >250 million people chronically infected with HBV, and these chronic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma. Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally, while most patients infected during adulthood develop acute hepatitis B (AHB), which usually results in viral clearance. HBV

Full Text available with Trip Pro

2017 Journal of Infectious Diseases

177. MKSAP: 25-year-old man positive for hepatitis B surface antigen

management? A. Administration of hepatitis B vaccine B. Administration of pegylated interferon C. Administration of tenofovir D. α-Fetoprotein measurement every 12 months E. Ultrasound imaging of the liver every 6 months MKSAP Answer and Critique The correct answer is E. Ultrasound imaging of the liver every 6 months. The most appropriate management is ultrasound imaging of the liver every 6 months. This patient from Africa has evidence of chronic hepatitis B virus (HBV) infection. In approximately 50 (...) MKSAP: 25-year-old man positive for hepatitis B surface antigen Screening and surveillance for hepatocellular carcinoma MKSAP: 25-year-old man positive for hepatitis B surface antigen | | December 2, 2017 13 Shares Test your medicine knowledge with the , in partnership with the . A 25-year-old man is evaluated in follow-up after recently testing positive for hepatitis B surface antigen. He underwent testing as part of the immigration process from Somalia. Two other siblings also have hepatitis

2017 KevinMD blog

178. Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation

should: monitor patients for respiratory signs and symptoms throughout treatment advise patients to report new signs of infection, including fever or respiratory symptoms promptly consider discontinuing bendamustine if there are signs of opportunistic infections Hepatitis B virus reactivation Reactivation of hepatitis B virus in chronic carriers of the virus has been reported after bendamustine. Some cases resulted in acute hepatic failure or a fatal outcome. Closely monitor carriers of hepatitis B (...) : Therapeutic area: , , Contents Advice for healthcare professionals: advise patients to report promptly new signs of infection, including fever or respiratory symptoms, and consider discontinuing bendamustine if there are signs of opportunistic infections monitor patients for opportunistic infections as well as cardiac, neurological, and respiratory adverse events hepatitis B virus (HBV) reactivation has also been reported; monitor known carriers of HBV for signs and symptoms of active HBV infection

Full Text available with Trip Pro

2017 MHRA Drug Safety Update

179. Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity. (PubMed)

expression was confirmed and maintained in a whole HBV context. Finally, viral spliced RNA detection related to a decrease of CCL2 expression in the livers of HBV chronic carriers underscored this mechanism.The microenvironment, modified by liver injury, increased HBSP RNA expression through splicing factor regulation, which in turn controlled hepatocyte chemokine synthesis. This feedback mechanism provides a novel insight into liver immunopathogenesis during HBV infection. Lay summary: Hepatitis B virus (...) Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity. Hepatitis B virus (HBV) RNA can undergo alternative splicing, but the relevance of this post-transcriptional regulation remains elusive. The mechanism of HBV alternative splicing regulation and its impact on liver pathogenesis were investigated.HBV RNA-interacting proteins were identified by RNA pull-down, combined with mass spectrometry analysis. HBV splicing regulation was investigated

Full Text available with Trip Pro

2017 Journal of Hepatology

180. Learn Which Cancer, Arthritis or Asthma Drugs Can Reactivate Hepatitis B – Even If You’ve Cleared the Infection

not mention (to) my oncologist that I was a carrier of hepatitis B, (because) I knew that it was not active. Then, after a week of chemo, I was really sick and got a high temperature. Then, my blood test came back (indicating) that my hepatitis B was reactivated. My liver doctor gave me medicine (an antiviral) to take to deactivate the virus.” Her oncologist immediately stopped chemotherapy and monitored her HBV DNA (viral load) and liver enzymes (ALT/SGPT) to make sure the antiviral lowered her viral (...) your hepatitis B and require monitoring and preventive use of antivirals to reduce reactivation risk, according to American Gastroenterological Association (AGA) : High-risk Drugs: More than 10 percent of people with current or resolved hepatitis B infections will experience a dangerous reactivation if treated with: Rituximab for non-Hodgkins lymphoma, or Ofatumumab for chronic lymphocytic leukemia Anyone with a current infection (HBsAg positive) treated with the following is also at high risk

2017 hepbblog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>